Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS ... INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH, SAN DIEGO, Aug. ... today that Kevin Gorman, President and Chief,Executive Officer will ... Boston and the NewsMakers in the Biotech Industry Conference,in ...
... today announced it was named to Inc. magazine’s ... nationwide for a second consecutive year. The firm ... range of industries, helping companies operate more efficiently ... of the Chicago area’s top 100 businesses, growing ...
... ( www.chemlifecycle.com ) has finalized an agreement today with Chemical ... Management Systems (EMS) software for their new venture. , ... ... -- Chemical Lifecycle Management - a strategic alliance formed by ...
Cached Biology Technology:Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference 2 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Chemical Lifecycle Management Chooses Chemical Safety's EMS Software 2
(Date:7/29/2014)... ground breaking new book that brings together two of ... raise the profile of insect fossils through stunning photographs ... Penney and James E Jepson, details the incredible preservation ... setting the scene for what these remarkable fossils can ... even the future of our planet. Like the mosquito ...
(Date:7/29/2014)... of cell, including sperm, bacteria and algae, propel ... protrusions, about one-hundredth of a millimetre long, function ... Similar, shorter structures called cilia are found on ... roles such as moving liquids over the cell. ... they transport mucus and expel pathogens from our ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2
... WI, JUNE 30, 2011 -- Agroforestry, the deliberate placement ... capture substantial amounts of carbon on agricultural lands while ... tools for accurately estimating current and projected carbon values ... an effective carbon-capturing option. Only occupying about 2 to ...
... scientific results from an ambitious voyage led by a group ... San Diego offer a stark view of human pollution and ... been labeled as the "Great Pacific Garbage Patch." Two ... or SEAPLEX, found evidence of plastic waste in more than ...
... HFES invites you to register to attend the 55th ... Red Rock Hotel in Las Vegas! Early bird discounts ... the Registration Information page at http://www.hfes.org/web/HFESMeetings/2011registration.html for ... more. Online registration is available at http://tinyurl.com/3drb8hz . ...
Cached Biology News:Scripps study finds plastic in 9 percent of 'garbage patch' fishes 2Scripps study finds plastic in 9 percent of 'garbage patch' fishes 3HFES 2011 registration is now open 2
adult...
DNA Purification...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: